Trials / No Longer Available
No Longer AvailableNCT02090127
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AVEO Pharmaceuticals, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Detailed description
This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ficlatuzumab | humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator |
Timeline
- First posted
- 2014-03-18
- Last updated
- 2015-07-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02090127. Inclusion in this directory is not an endorsement.